These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 18589118

  • 1. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.
    Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A.
    Transplant Proc; 2008 Jun; 40(5):1407-10. PubMed ID: 18589118
    [Abstract] [Full Text] [Related]

  • 2. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.
    Clin Transplant; 2008 Jun; 22(1):89-97. PubMed ID: 18217909
    [Abstract] [Full Text] [Related]

  • 3. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF, Hodson EM, Jones C, Craig JC.
    Transplantation; 2006 Jan 27; 81(2):139-45. PubMed ID: 16436954
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, Chandrasekar P, Gruber SA.
    Clin Transplant; 2007 Jan 27; 21(4):466-71. PubMed ID: 17645705
    [Abstract] [Full Text] [Related]

  • 5. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 6. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G, Daniel V, Naujokat C, Döhler B.
    Transplantation; 2009 Oct 27; 88(8):962-7. PubMed ID: 19855238
    [Abstract] [Full Text] [Related]

  • 7. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.
    Transplantation; 2012 Jun 15; 93(11):1075-85. PubMed ID: 22683823
    [Abstract] [Full Text] [Related]

  • 8. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients.
    Ozaki KS, Câmara NO, Galante NZ, Camargo LF, Pacheco-Silva A.
    Int Immunopharmacol; 2005 Jan 15; 5(1):103-6. PubMed ID: 15589467
    [Abstract] [Full Text] [Related]

  • 9. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation.
    Gómez E, Laurés A, Baltar JM, Melón S, Díez B, de Oña M.
    Transplant Proc; 2005 Nov 15; 37(9):3760-3. PubMed ID: 16386530
    [Abstract] [Full Text] [Related]

  • 10. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Nov 15; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 11. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.
    Ghassemieh B, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, DeOliveira NC, Vigneswaran WT, Charbeneau J, Garrity ER, Bhorade SM.
    J Heart Lung Transplant; 2013 Jul 15; 32(7):701-6. PubMed ID: 23664526
    [Abstract] [Full Text] [Related]

  • 12. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.
    San Juan R, Aguado JM, Lumbreras C, Fortun J, Muñoz P, Gavalda J, Lopez-Medrano F, Montejo M, Bou G, Blanes M, Ramos A, Moreno A, Torre-Cisneros J, Carratalá J, RESITRA Network of the Spanish Study Group of Infection in Transplantation.
    Clin Infect Dis; 2008 Oct 01; 47(7):875-82. PubMed ID: 18752439
    [Abstract] [Full Text] [Related]

  • 13. Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation.
    Cervera C, Lozano F, Linares L, Antón A, Balderramo D, Suárez B, Pascal M, Sanclemente G, Cofán F, Ricart MJ, Navasa M, Roig E, Marcos MA, Pumarola T, Moreno A.
    Transplant Proc; 2009 Oct 01; 41(6):2259-61. PubMed ID: 19715891
    [Abstract] [Full Text] [Related]

  • 14. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 01; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 15. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
    Roman A, Manito N, Campistol JM, Cuervas-Mons V, Almenar L, Arias M, Casafont F, del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI, Jara P, Morales JM, Navarro M, Oppenheimer F, Prieto M, Pulpón LA, Rimola A, Serón D, Ussetti P, ATOS working group.
    Transplant Rev (Orlando); 2014 Apr 01; 28(2):84-91. PubMed ID: 24602805
    [Abstract] [Full Text] [Related]

  • 16. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
    Ozaki KS, Câmara NO, Nogueira E, Pereira MG, Granato C, Melaragno C, Camargo LF, Pacheco-Silva A.
    Clin Transplant; 2007 Apr 01; 21(5):675-80. PubMed ID: 17845644
    [Abstract] [Full Text] [Related]

  • 17. [Infections in organ transplantations].
    Holzinger C, Buxbaum P, Laczkovics A, Domanig E, Wolner E.
    Zentralbl Chir; 1990 Apr 01; 115(17):1091-9. PubMed ID: 2173865
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis.
    Fan Y, Xiao YB, Weng YG.
    Transplant Proc; 2009 Jun 01; 41(5):1821-4. PubMed ID: 19545736
    [Abstract] [Full Text] [Related]

  • 19. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 01; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 20. Impact and management of hyperlipidemia posttransplantation.
    Fellström B.
    Transplantation; 2000 Dec 15; 70(11 Suppl):SS51-7. PubMed ID: 11152232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.